The Pakistan Competition Commission clears an acquisition, following an in-depth investigation, in the pharmaceutical sector (Novartis / GSK)

Competition Authority, Pakistan

Previous article The Pakistan Competition Commission clears a merger subject to remedies in the pharmaceutical sector (GSK / Novartis) Next article The EU Commission conditionally approves deals in the pharmaceutical sector extending its analysis of pipeline pharmaceutical products (Novartis / GSK)

9 Feb 2015

The Pakistan Competition Commission clears an acquisition, following an in-depth investigation, in the pharmaceutical sector (Novartis / GSK)

KEYWORDS

Reference

Pakistan Competition Commission (Islamabad), Novartis / GlaxoSmithKline, Press Release, 9 February 2015

The Competition Commission clears phase II review of the proposed acquisition by novartis ag of the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline plc* ISLAMABAD, MONDAY, 09 FEBRUARY 2015: The Competition Commission of Pakistan ("Commission") has concluded the Phase II review of the pre-merger application dated 29 August, 2014 by clearing the proposed acquisition by which Novartis AG (“Novartis”), intends to acquire the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

Pakistan Competition Authority
Competition Commission of Pakistan (Islamabad)

Pakistan 11 contributions 1590 visits

Quotation

Pakistan Competition Authority, The Pakistan Competition Commission clears an acquisition, following an in-depth investigation, in the pharmaceutical sector (Novartis / GSK), 9 February 2015, e-Competitions Pharma & Mergers, Art. N° 71451

Visites 154